NL-OMON27495招募中不适用
Prostate Cancer Molecular Medicine (PCMM).
Erasmus MC, NKI-AvL, UMCG, UMC0 个研究点目标入组 400 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 发起方
- 入组人数
- 400
研究概览
简要总结
/A
研究设计
- 研究类型
- Observational
入排标准
入选标准
- •1. Planned to undergo prostate biopsies according to standard practice;
排除标准
- •Group 1 and group 2:
- •1. Known allergy to contrast agents or sulphur hexafluoride micro bubbles;
研究者
相似试验
已完成
不适用
Prostate Cancer Molecular Medicineprostate carcinoma1003859710036958Prostate cancerNL-OMON39774Erasmus MC, Universitair Medisch Centrum Rotterdam496
已完成
不适用
Prostate Cancer Molecular Medicine: Transition Grant 2015 (ProCaMolMed)Prostate cancerNL-OMON42675Erasmus MC, Universitair Medisch Centrum Rotterdam525
终止
不适用
Exploring Genomic, Proteomic and Dosimetric Determinants of Late Toxicity After Three Dimensional Conformal Radiotherapy (RT) for Prostate CancerProstate CancerNCT00122265AHS Cancer Control Alberta83
招募中
不适用
Intrinsic Validity of Molecular Marker(s) Detection on Tissular Tumoral DNA to Predict the Efficacy of 177Lutetium-PSMA-617 (Lu-PSMA) Treatment for Castration-resistant Metastatic Prostate CancerCastration-resistant Metastatic Prostate CancerTreated by 177Lutetium-PSMA-617 (Lu-PSMA)NCT06600802Centre Jean Perrin120
招募中
不适用
The Investigation of New Biological Markers for Prostate Cancer Diagnosis and Management in Chinese PopulationProstate CancerNCT03893929Chinese University of Hong Kong5,000